This Colorectal Cancer Trial Had a 100% Cure Rate — What They Did @DrBeenMedicalLectures
This Colorectal Cancer Trial Had a 100% Cure Rate — What They Did  @DrBeenMedicalLectures
Uploaded June 2022 | Updated November 2026, 3 hours ago
A groundbreaking clinical trial reported a 100% remission rate in colorectal cancer patients using Dostarlimab, a PD-1 blocking immunotherapy drug.

In this video, Dr. Mobeen Syed delves into:
The mechanism of action of Dostarlimab.
An overview of the clinical trial's design and its remarkable outcomes.
Implications of these findings for the future of colorectal cancer treatment.

Could this signify a transformative moment in cancer therapy? Let's explore the details.

Link to the FDA channel: youtube.com/watch?v=DfdMsAqkneE

🧠 Study Links:
Sloan Kettering Report: mskcc.org/news/rectal-cancer-disappears-after-experimental-use-immunotherapy
NEJM Study: nejm.org/doi/pdf/10.1056/NEJMoa2201445?articleTools=true

Want to support this work?
Lifetime Membership Offer: drbeen.com/yt-special-p
Buy Me a Coffee: buymeacoffee.com/DrMobeenSyed
Substack: mobeensyedmd.substack.com
Patreon: patreon.com/mobeensyed

#drbeen #koolbeens #cancer

Disclaimer:
This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.



URL list from Wednesday, Jun. 8 2022

DrBeen: Medical Education Online
drbeen.com

Rectal Cancer Disappears After Experimental Use of Immunotherapy | Memorial Sloan Kettering Cancer Center
mskcc.org/news/rectal-cancer-disappears-after-experimental-use-immunotherapy

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
nejm.org/doi/pdf/10.1056/NEJMoa2201445?articleTools=true

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors - Full Text View - ClinicalTrials.gov
clinicaltrials.gov/ct2/show/NCT04165772

Dostarlimab - Wikipedia
en.wikipedia.org/wiki/Dostarlimab

Programmed cell death protein 1 - Wikipedia
en.wikipedia.org/wiki/Programmed_cell_death_protein_1

Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek - PMC
ncbi.nlm.nih.gov/pmc/articles/PMC2492504

Ectodomain - Wikipedia
en.wikipedia.org/wiki/Ectodomain

Treatment | Global Colon Cancer Association
globalcca.org/treatment

Colorectal Cancer Stages | Rectal Cancer Staging | Colon Cancer Staging
cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/staged.html
This Colorectal Cancer Trial Had a 100% Cure Rate — What They DidOreo Cookies Reduce LDL More Than StatinsAllergic Reactions and Death By Pfizer-BioNTech VaccineTop Supplements That Actually Fight Inflammation (Backed by Science)Beat Chronic Inflammation with This 3-Step PlanTreatment Resistant Depression? This Study Offers a SolutionGame Changer: Over-the-Counter CGM: A New Era for Diabetics and BiohackersCOVID-19 Causes Long-Term Blood Cell ChangesInflammation Beats Cholesterol for Cardiovascular DiseaseChronic Inflammation - Immune System Regulation (Lecture 3)DexamethasoneBrain Autoimmunity in Long COVID: MBP, MOG, Attacked!
Drbeen Medical Lectures |

This Colorectal Cancer Trial Had a 100% Cure Rate — What They Did

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER